07:00 , May 14, 2007 |  BioCentury  |  Finance

Ebb & Flow

A few cancer vaccine companies and insiders managed to capitalize on rising share prices during the brief window between the March 29 FDA panel vote in favor of Dendreon's Provenge sipuleucel-T for prostate cancer and...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

Beacon Sciences, University of Texas deal

Beacon received an exclusive license to the university’s chemiluminescent synthetic receptor assay technology for detecting chemical and biological agents for medical, environmental and industrial diagnostic applications. Further details were not disclosed. Beacon Sciences LLC ,...